Skip to main content

MK-677 (Ibutamoren) vs Ipamorelin

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

MK-677 (Ibutamoren)

MK-677, also known as Ibutamoren, is an orally active growth hormone secretagogue. Unlike peptides, it can be taken orally and has a long half-life, providing 24-hour GH elevation.

Full details →

Ipamorelin

Ipamorelin is a selective growth hormone secretagogue that stimulates the release of growth hormone from the pituitary gland without significantly affecting cortisol or prolactin.

Full details →

Side-by-Side Comparison

AspectMK-677 (Ibutamoren)Ipamorelin
MechanismActs as a potent, selective agonist of the ghrelin receptor (GHS-R1a). Increases GH and IGF-1 levels without affecting cortisol. Mimics ghrelin's GH-releasing effects.Acts as a ghrelin mimetic, binding to the ghrelin receptor (GHS-R) in the pituitary to stimulate GH release. Highly selective with minimal effect on other hormones.
Typical DosageTypical dosing: 10-25mg taken orally once daily. Often taken at night due to sleep benefits and appetite increase.Typical dosing ranges from 200-300mcg administered 2-3 times daily, often combined with CJC-1295.
AdministrationOral administration (capsule or liquid). Can be taken with or without food. Long half-life allows once-daily dosing.Subcutaneous injection. Best results when administered fasted or before sleep. Often stacked with GHRH peptides.
Side EffectsIncreased appetite and water retention are most common. May cause lethargy, vivid dreams, and mild numbness. Can affect blood glucose and insulin sensitivity.Generally well-tolerated. May cause mild headaches, lightheadedness, or increased hunger initially.
Best For

What They Have in Common

Both MK-677 (Ibutamoren) and Ipamorelin are commonly used for:

Detailed Analysis

Both Ipamorelin and MK-677 (Ibutamoren) are commonly used for Muscle Growth, Fat Loss, Recovery & Healing, Sleep Quality.

Which Should You Choose?

Ipamorelin has stronger evidence for Fat Loss.

Ready to Learn More?